O PAPEL DA VITAMINA D NA RESISTÊNCIA À INSULINA EM IDOSOS | THE ROLE OF VITAMIN D IN INSULIN RESISTANCE IN THE ELDERLY
Resumo
RESUMO
Introdução: A hipovitaminose D tem grande impacto a nível mundial estimando-se a sua prevalência em 52 a 77%. Vários
estudos têm demonstrado haver correlação entre baixos níveis séricos de 25-hidroxivitamina D e o risco aumentado de diabetes
mellitus tipo 2. Este estudo teve como objectivo investigar o efeito da correcção da hipovitaminose D na insulinorresistência.
Métodos: Foi utilizada uma amostra de conveniência com 10 doentes (6 mulheres e 4 homens) suplementados com
vitamina D durante 4 meses. Como critérios de inclusão foram consideradas: idade superior a 65 anos, insulinorresistência
– homeostasis model assesment 1 (HOMA-1) superior a 2 e hipovitaminose D (25-hidroxivitamina D sérica inferior a 30 ng/ml).
Como critérios de exclusão foram considerados: diagnóstico prévio de diabetes mellitus tipo 2, glicémia em jejum superior
ou igual a 126 mg/dl, terapêutica com antidiabéticos ou corticoterapia, suplementação com vitamina D nos últimos 6 meses
e hipercalcémia (cálcio corrigido para a albumina ≥10,5 mg/dl).
Resultados: Verificou-se um aumento estatisticamente significativo nos níveis séricos de 25-hidroxivitamina D após suple-
mentação, mas não no HOMA-1.
Discussão: Dada a pequena dimensão da amostra e a restrição dos critérios de inclusão, serão necessários mais estudos para
perceber a relação da hipovitaminose D com a insulinorresistência e assim com o aumento do risco para diabetes mellitus tipo 2.
Palavras-chave: Vitamina D; Resistência à insulina; Diabetes melittus tipo 2; Idoso
ABSTRACT
Introduction: Vitamin D deficiency has a worldwide impact, with a 52 to 72% prevalence. Several studies show a correlation between
low 25-hidroxyvitamin D and increased risk for type 2 diabetes. The goal of this study was to document the effect of vitamin D correction in
insulin resistance.
Methods: A convenience sample of 10 patients (6 females and 4 males) was supplemented with vitamin D for a 4 month period. The
inclusion criteria included insulin resistance (with a homeostasis model assessment 1 – HOMA 1 – above 2), age older than 65 years and
vitamin D deficiency (25-hidroxyvitamin D below 30ng/mL). A previous diagnosis of diabetes, corticosteroid treatment, hypercalcaemia
(albumin corrected calcium ≥10,5 mg/dl) and vitamin D supplementation were considered exclusion criteria.
Results: There was a statistically significant increase in 25-hidroxyvitamin D levels after supplementation but not in HOMA-1.
Discussion: Due to the small sample size and inclusion criteria restrictions, more studies are needed to fully understand the relationship
between low vitamin D and insulin resistance, as well as increased risk for type 2 diabetes.
Keywords: Vitamin D; Insulin resistance; Diabetes mellitus type 2; Aging
Texto Completo:
PDFReferências
Wolpowitz D, Gilchrest BA. The vitamin D questions: How much do you need and how should you get it? J Am Acad Dermatol. 2006;
(2): 301-17.
Lamprecht SA, Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer.
; 3 (8): 601-14.
Lips P, Hosking D, Lippuner K, Norquist JM, Wehren L, Maalouf G, et al. The prevalence of vitamin D inadequacy amongst women with
osteoporosis: An international epidemiological investigation. J Intern Med. 2006; 260 (3): 245-54.
Holick MF, Matsuoka LY, Wortsman J. Age, vitamin D, and solar ultraviolet. Lancet. 1989; 2 (8671): 1104-5.
van der Wielen RPJ, de Groot LCPGM, van Staveren WA, Löwik MRH, van den Berg H, Haller J, et al. Serum vitamin D concentrations among
elderly people in Europe. Lancet. 1995; 346 (8969): 207-10.
Gloth FM, Gundberg CM, Hollis BW, Haddad JG, Tobin JD. Vitamin-D deficiency in homebound elderly persons. JAMA. 1995; 274 (21): 1683-6.
Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D’Erasmo E, et al. Short and long-term variations in serum calciotropic hormones after
a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008; 93 (8): 3015-20.
Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004; 89 (11): 5387-91.
Schreuder F, Bernsen RMD, van der Wouden JC. Vitamin D Supplementation for nonspecific musculoskeletal pain in Non-Western immigrants:
A randomized controlled trial. Ann Fam Med. 2012; 10 (6): 503-9.
de Torrenté de la Jara G, Pécoud A, Favrat B. Musculoskeletal pain in female asylum seekers and hypovitaminosis D3. BMJ. 2004; 329 (7458): 156-7.
Turner MK, Hooten WM, Schmidt JE, Kerkvliet JL, Townsend CO, Bruce BK. Prevalence and clinical correlates of vitamin D inadequacy
among patients with chronic pain. Pain Med. 2008; 9 (8): 979-84.
Garland CF, Kim JJ, Mohr SB, Gorham ED, Grant WB, Giovannucci EL, et al. Meta-analysis of all-cause mortality according to serum
-hydroxyvitamin D. Am J Public Health. 2014; 104 (8): e43-50.
Schöttker B, Ball D, Gellert C, Brenner H. Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of
prospective cohort studies. Ageing Res Rev. 2013; 12 (2): 708-18.
Heaney RP. The vitamin D requirement in health and disease. J Steroid Biochem Mol Biol. 2005; 97 (1-2): 13-9.
Romagnoli E, Mascia ML, Cipriani C, Fassino V, Mazzei F, D’Erasmo E, et al. Short and long-term variations in serum calciotropic hormones after
a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008; 93 (8): 3015-20.
Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004; 89 (11): 5387-91.
Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007; 85 (1): 6-18.
Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and
diabetes mellitus. Diabetes Res Clin Pract 1995;27:181–8.
Pietschmann P, Schernthaner G, Woloszczuk W. Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular
complications. Diabetologia 1988;31:892).
Isaia G, Giorgino R, Adami S. High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 2001;24:1496(letter).
Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ. Glucose intolerance and impairment of insulin secretion in relation to vitamin D
deficiency in east London Asians. Diabetologia 1995;38:1239–45.
Forouhi NG, Luan Ja, Cooper A, et al. (2008) Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance:
The Medical Research Council Ely. Prospective Study 1990–2000. Diabetes 57, 2619–262.
Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity
in type 2 diabetic patients. Int J Clin Pract 2003; 57: 258–261.
Nagpal J, Pande JN & Bhartia A (2009) A double-blind, randomized, placebo-controlled trial of the short-term effect of itamin D3 supplementation
on insulin sensitivity in apparently healthy,
Bonora E, Targher G, Alberiche M, et al. (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment
of insulin sensitivity. Diabetes Care 23,57–63.
Wallace T, Levy J & Matthews D (2004) Use and abuse of HOMA modelling. Diabetes Care 27, 1487–1495.
Gayoso-Diz P, González A, Rodriguez-Alvarez M, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general
adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocrine Disorders 2013, 13:47.
Apontamentos
- Não há apontamentos.